Clinical Trial Update: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the combination of cixutumumab and doxorubicin in patients with unresectable, locally advanced, or metastatic soft tissue sarcoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Desmoplastic Small Round Cell Tumor
• Epithelioid Sarcoma
• Leiomyosarcoma
• Liposarcoma
• Rhabdomyosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• Cixutumumab (Cixutumumab)
• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Status: COMPLETED